Biosimilars News

News

Cost-Effectiveness of Primary Prophylaxis With G-CSF Biosimilars in Patients at Risk of Febrile Neutropenia

06/12/2022

PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.

PEG biosimilars may be able to...

06/12/2022

Journal of Clinical Pathways

News

Trastuzumab Biosimilar Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer Treated With Chemotherapy

06/09/2022

Ellen Kurek ;

A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.

A research group in Denmark...

06/09/2022

Journal of Clinical Pathways

News

Bevacizumab-bvzr Biosimilar Used Most Frequently for Metastatic Colorectal Cancer in US Oncology Practice, According to Retrospective Cohort Study

06/09/2022

Ellen Kurek ;

This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.

This study finds that US...

06/09/2022

Journal of Clinical Pathways

News

Outcomes of Treatment With Cancer Biosimilars Found Equal to Those of the Reference Drug in Harvard Systematic Review and Meta-Analysis

05/11/2022

Ellen Kurek ;

Study findings show that results of rigorous clinical evaluation of cancer drug biosimilars were statistically indistinguishable when compared with the results of evaluations of the reference drug across subgroups of drugs, cancer types, and...

Study findings show that results...

05/11/2022

Journal of Clinical Pathways

News

04/14/2022

Ellen Kurek ;

Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.

Biosimilar HD201 demonstrates...

04/14/2022

Journal of Clinical Pathways

News

Trastuzumab Biosimilars Safe, Effective Among Patients With HER2-Positive Breast Cancer

03/07/2022

Marta Rybczynski ;

Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.

Study findings show that...

03/07/2022

Journal of Clinical Pathways

News

02/25/2022

Findings from a recent update on currently approved oncology biosimilars suggests that the use of biosimilars might provide competitive, lower-cost alternatives to biologics used in oncology.

Findings from a recent update on...

02/25/2022

Journal of Clinical Pathways

News

Cost-Effectiveness of Primary Prophylaxis With Biosimilar Filgrastim for Patients at Risk for Febrile Neutropenia

02/21/2022

Janelle Bradley ;

Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.

Study findings reveal primary...

02/21/2022

Journal of Clinical Pathways

News

Conversion to Biosimilar Neutropenia Prophylaxis Generates Cost-Savings and Provides Access to Pancreatic Cancer Treatment

02/11/2022

Janelle Bradley ;

Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.

Conversion to biosimilar...

02/11/2022

Journal of Clinical Pathways

News

02/10/2022

Janelle Bradley ;

Study findings suggest biosimilar intravenous trastuzumab-dkst is cost-efficient over reference intravenous and subcutaneous trastuzumab in metastatic breast cancer.

Study findings suggest...

02/10/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Biosimilars News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products